• Agnieszka Pluta, Tadeusz Robak, Barbara Cebula, Agata Majchrzak, Piotr Pluta, Kamil Brzozowski, Konrad Stępka, Anna Szmigielska-Kapłon, Olga Grzybowska-Izydorczyk, Magdalena Czemerska, Piotr Smolewski, and Agnieszka Wierzbowska.
• Department of Hematology, Medical University of Lodz, Lodz, Poland.
• Arch Med Sci. 2021 Jan 1; 17 (3): 700-707.

IntroductionThe misbalance between a family of inhibitor of apoptosis proteins (IAP), regulated by the nuclear factor kappa B (NF-κB) and their natural antagonist second mitochondrial-derived activator of caspases/direct IAP binding protein with low pI (Smac/DIABLO) are important to biology of acute myeloid leukemia (AML).Material And MethodsThe aim of the study was to assess NF-κB and Smac/DIABLO proteins expression in blasts of 109 newly diagnosed AML patients using the multicolor flow cytometry and evaluate their influence on AML patients outcome.ResultsExpression of NF-κB and of Smac/DIABLO proteins were found in 95% and 98% of the patients, respectively. A negative correlation between Smac/DIABLO and NF-κB was observed. Age < 60 years old as well as higher Smac/DIABLO expression were associated with a higher probability of complete response achievement in the multivariate analysis. Longer overall survival (OS) in the univariate and multivariate analyses was influenced by age < 60 years old, a favorable or intermediate-risk karyotype and high Smac/DIABLO expression. Additionally, in the survival analysis of the subgroups, the patients aged < 60 years old, with high Smac/DIABLO expression, lower NF-κB expression and < 50% of bone marrow blasts who were treated with standard treatment had better OS.ConclusionsLower NF-κB and higher Smac/DIABLO expression may influence AML patients outcome.Copyright: © 2019 Termedia & Banach.

4 keywords...

hide…